



**Written submission from
Bruce Power**

**Mémoire de
Bruce Power**

In the Matter of

À l'égard de

McMaster University

Université McMaster

Application to renew its McMaster Nuclear
Reactor Class IA non-power reactor operating
licence

Demande concernant le renouvellement de son
permis d'exploitation d'un réacteur de catégorie
IA non producteur de puissance pour le réacteur
nucléaire McMaster

Public Hearing - Hearing in writing based on
written submissions

Audience publique - Audience fondée sur des
mémoires

April 2024

Avril 2024

March 8, 2024

Senior Tribunal Officer, Secretariat
Canadian Nuclear Safety Commission
280 Slater Street, P.O. Box 1046, Station B
Ottawa, Ontario K1P 5S9
Email: interventions@cnsccsn.gc.ca

Attention: Canadian Nuclear Safety Commission (CNSC) Tribunal Chair and Commission Members

RE: McMaster University Research Reactor Licence Renewal (Licence #NPROL-01)

I am writing this letter in support of the McMaster University Research Reactor Licence renewal (#NPROL-01).

The McMaster Nuclear Reactor has played an integral role in helping to make Ontario and Canada a leader in the nuclear research and a world superpower in the production of medical isotopes.

Since becoming operational in 1959, this multi-purpose research facility and reactor have helped Canada blossom into a leader in the nuclear industry by driving research, education, and expertise in the nuclear field.

For more than a half-century, Canada has led the way internationally when it comes to the research, development and production of medical isotopes and radiopharmaceuticals, with the McMaster University Research Reactor playing a key role in building this strong foundation. Along with Bruce Power and the other members of the Canadian Nuclear Isotope Council, McMaster is helping to ensure we continue this leadership role in improving people's lives around the world.

The McMaster Nuclear Reactor is a world leader in the production of iodine-125, a radioactive isotope that is used in the treatment of prostate cancer, with 70,000 treatments a year being sent around the world. McMaster recently manufactured and packaged its first patient dose of holmium-166 for liver cancer treatment trials.

The reactor conducts important neutron beam research and development, and conducts neutron irradiation in support of other Canadian industries, such as mining exploration and environmental sampling, etc.

McMaster University also aligns with Bruce Power and the Canadian Nuclear industry in their goals of powering a clean energy future through its research and solutions.

McMaster University has been a leader in Small Modular Reactor research in design, deployment and safety of the emerging technology that has been part of the province's *Powering Ontario's Growth* plan.

Our nuclear advantage is clear. Canada and Ontario are starting from a position of strength when it comes to decarbonizing and electrifying our economy and in our leadership in supplying cancer-fighting medical isotopes to the world health-care community.

It's imperative that we continue to support and collaborate with McMaster University as it continues to foster the understanding and importance of the nuclear industry through research and education.

Renewing McMaster's Research Reactor Licence is not only in the best interest of the nuclear industry, but for all Canadians as we seek to meet climate change goals and support the world medical community.

Regards,



Mike Rinker,
Vice-President, Regulatory, Environment and Sustainability
Bruce Power